2024
Gender disparities in utilization of statins for low density lipoprotein management across the spectrum of atherosclerotic cardiovascular disease: Insights from the houston methodist cardiovascular disease learning health system registry
Shahid I, Satish P, Gullapelli R, Nicholas J, Javed Z, Avenatti E, Bose B, Mahajan S, Roy T, Sharma G, Rodriguez F, Andrieni J, Jones S, Al-Kindi S, Cainzos-Achirica M, Nasir K. Gender disparities in utilization of statins for low density lipoprotein management across the spectrum of atherosclerotic cardiovascular disease: Insights from the houston methodist cardiovascular disease learning health system registry. American Journal Of Preventive Cardiology 2024, 19: 100722. PMID: 39281350, PMCID: PMC11402022, DOI: 10.1016/j.ajpc.2024.100722.Peer-Reviewed Original ResearchHigh-intensity statinsRacial/ethnic subgroupsSystem registryStatin utilizationLDL-CHigh-intensity statin useGender disparitiesSocioeconomic risk factorsLDL-C managementUS healthcare systemMultivariate logistic regression analysisLDL-C goalsLDL-C <Utilization of statinsAtherosclerotic cardiovascular diseaseLogistic regression analysisSocioeconomic subgroupsHealthcare systemStatin uptakeStatin useAdult patientsLipid managementLipoprotein managementStatinsSignificant gender disparityIndividualized Dose-Response to Statins Associated With Cardiovascular Disease Outcomes
Aggarwal S, Jiang L, Liu G, Grabowska M, Ong H, Wilke R, Feng Q, Wei W. Individualized Dose-Response to Statins Associated With Cardiovascular Disease Outcomes. JACC Advances 2024, 3: 100894. PMID: 38737008, PMCID: PMC11086740, DOI: 10.1016/j.jacadv.2024.100894.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseAtherosclerotic cardiovascular disease eventsLDL-CComposite primary end pointPrevention of atherosclerotic cardiovascular diseaseDose responseLow-density lipoprotein cholesterolBaseline LDL-CPrimary end pointAll-Cause MortalityElectronic health record dataTime-to-event analysisHealth record dataCardiovascular disease outcomesIndividual dose responsesMultiple dosesClinical outcomesPrescribed statinsLipoprotein cholesterolHazard ratioStatinsEnd pointsDisease outcomeCardiovascular diseaseED50
2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupUncovering the Relationship Between Statins and Muscle Problems in the ELSA-Brasil MSK Cohort
Pedroso A, Barreto S, Telles R, Machado L, Haueisen Sander Diniz M, Duncan B, Figueiredo R. Uncovering the Relationship Between Statins and Muscle Problems in the ELSA-Brasil MSK Cohort. Cardiovascular Drugs And Therapy 2023, 38: 1409-1414. PMID: 37261675, DOI: 10.1007/s10557-023-07476-7.Peer-Reviewed Original ResearchConceptsFive-times-sit-to-standStatin useMSK cohortMuscle problemsELSA-BrasilMuscle painHandgrip testFive-times-sit-to-stand testDuration of statin treatmentSecondary analysisMultivariate logistic regression analysisBrazilian civil servantsLogistic regression analysisNo significant associationSelf-reported symptomsCross-sectional data analysisStatin treatmentEfficacy-effectiveness gapMuscle strengthHandgrip strengthHighest quintileMuscle groupsMuscle weaknessStatinsPain
2022
Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease
Nanna M, Nelson A, Haynes K, Shambhu S, Eapen Z, Cziraky M, Calvert S, Pagidipati N, Granger C. Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease. Journal Of The American Geriatrics Society 2022, 71: 1243-1249. PMID: 36538393, PMCID: PMC10089944, DOI: 10.1111/jgs.18172.Peer-Reviewed Original ResearchConceptsHigh-intensity statinsLipid-Lowering TherapyModerate-intensity statinsU.S. older adultsOlder adultsPCSK9 inhibitorsNon-statin lipid-lowering therapyMulticenter retrospective cohort studyRetrospective cohort studyMinority of patientsAtherosclerotic cardiovascular diseaseCoronary artery diseaseEligible older adultsCohort studyOlder patientsOverall cohortArtery diseaseIntensive treatmentCardiovascular diseaseASCVDSecondary measuresStatinsUntreated individualsPatientsTherapyStatins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation
Coburn SB, Lang R, Zhang J, Palella FJ, Horberg MA, Castillo-Mancilla J, Gebo K, Galaviz KI, Gill MJ, Silverberg MJ, Hulgan T, Elion RA, Justice AC, Moore RD, Althoff KN, Research and Design of IeDEA F. Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 91: 469-478. PMID: 36053091, PMCID: PMC9649872, DOI: 10.1097/qai.0000000000003083.Peer-Reviewed Original ResearchConceptsACC/AHA guidelinesStatin initiationStatin eligibilityAHA guidelinesTreatment gapNorth American AIDS Cohort CollaborationATP III guidelinesCohort CollaborationPrevalence ratiosUS cohortStatin utilizationEligibility criteriaStatinsPoisson regressionConfidence intervalsAnnual proportionHIVPWHEligibilityAppropriate candidatesCalendar yearPredictorsGuidelinesInitiationCohortContemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
Shen M, Nargesi A, Nasir K, Bhatt DL, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States. Journal Of The American Heart Association 2022, 11: e026075. PMID: 36102276, PMCID: PMC9683659, DOI: 10.1161/jaha.122.026075.Peer-Reviewed Original ResearchConceptsLipid-Lowering TherapyIcosapent ethylCardiology/American Heart Association (ACC/AHA) guideline recommendationsNutrition Examination Survey dataAddition of ezetimibeUse of statinsClinical practice guidelinesCurrent statin usePopulation health outcomesConclusions SixCardiovascular outcomesStatin useClinical profileGuideline recommendationsLipid profileNational HealthPCSK9iNovel therapiesNovel agentsPractice guidelinesUS adultsAmerican CollegeStatinsHealth outcomesTherapy
2021
Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack
Dearborn-Tomazos JL, Hu X, Bravata DM, Phadke MA, Baye FM, Myers LJ, Concato J, Zillich AJ, Reeves MJ, Sico JJ. Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack. Stroke 2021, 52: 2521-2529. PMID: 34015937, DOI: 10.1161/strokeaha.120.030089.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokeIschemic attackHospital dischargeHospital admissionHigh mortalityVeterans Health Administration facilitiesHigh-potency statinsUnderutilization of statinsHigh potencyStatin doseStatin medicationBaseline characteristicsMost patientsPrescribed statinsStatin treatmentPharmacy filesStatin potencyAtherosclerotic originUS veteransPractice guidelinesStudy populationHigher oddsPatientsStatinsGenetic determinants of LDL cholesterol and risk of intracerebral haemorrhage
Szejko N, Kirsch E, Falcone GJ. Genetic determinants of LDL cholesterol and risk of intracerebral haemorrhage. Current Opinion In Lipidology 2021, 32: 244-248. PMID: 34010223, PMCID: PMC10273781, DOI: 10.1097/mol.0000000000000761.Peer-Reviewed Original ResearchConceptsRisk of ICHIntracerebral hemorrhageLDL levelsLDL cholesterolInverse associationClinical trialsLipid levelsObservational studyCerebral small vessel diseaseWhite matter hyperintensity volumeLDL cholesterol levelsLow LDL levelsNontraumatic intracerebral hemorrhageSmall vessel diseaseElevated LDL levelsElevated lipid levelsVessel diseaseCholesterol levelsHigh burdenHyperintensity volumeHigh riskRole of lipidsHemorrhageStatinsRiskIs the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging
Xu M, Demuyakor A, Hu S, Liu H, Zhao C, Chen T, Qin Y, Xu Y, Feng X, Zeng M, Weng Z, Gao Z, Hou J, Jia H, Zhang S, Yu B. Is the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging. Catheterization And Cardiovascular Interventions 2021, 97: 1097-1107. PMID: 33864710, DOI: 10.1002/ccd.29654.Peer-Reviewed Original ResearchConceptsOptical coherence tomographyLipid-rich plaquesLipid lowering therapyEffect of atorvastatinFibrous cap thicknessStatin therapyLowering therapyCoherence tomographyIntensive lipid lowering therapySerial optical coherence tomographyCholesterol levelsLow-density lipoprotein cholesterol levelsIntravascular ultrasound imagingLipoprotein cholesterol levelsCholesterol level reductionLipid arcClinical benefitFollow-upPlaque volumeUltrasound imagingTherapyTherapy effectsPlaque burdenPercentage changeStatinsPrevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Thomson MJ, Serper M, Khungar V, Weiss LM, Trinh H, Firpi-Morell R, Roden M, Loomba R, Barritt AS, Gazis D, Mospan AR, Fried MW, Reddy KR, Lok AS. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical Gastroenterology And Hepatology 2021, 20: 458-460.e4. PMID: 33775894, PMCID: PMC8464616, DOI: 10.1016/j.cgh.2021.03.031.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseStatin useReal-world cohortCoenzyme reductase inhibitorsHepatic decompensationCardiovascular eventsPatient factorsCardiovascular diseasePatientsLower mortalityReductase inhibitorsStatinsDiseasePrevalenceRiskDecompensationCarcinomaHepatotoxicityCohortMortality
2020
Guideline-Based Medications for Older Adults Discharged after Percutaneous Coronary Intervention in a Suburban City of Japan: A Cohort Study Using Claims Data
Shimada K, Hamada S, Sawano M, Yamamoto H, Yoshie S, Iijima K, Miyata H. Guideline-Based Medications for Older Adults Discharged after Percutaneous Coronary Intervention in a Suburban City of Japan: A Cohort Study Using Claims Data. The Tohoku Journal Of Experimental Medicine 2020, 252: 143-152. PMID: 33028759, DOI: 10.1620/tjem.252.143.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsFemaleGeriatricsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInsurance Claim ReviewJapanMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionOdds RatioPatient DischargePercutaneous Coronary InterventionPractice Guidelines as TopicRetrospective StudiesSecondary PreventionConceptsPercutaneous coronary interventionGuideline-based medicationsSecondary preventionΒ-blockersCohort studyCoronary interventionPrescription ratesClaims dataMultivariable logistic regression analysisOlder groupOlder adultsPrescription of antiplateletACEI/ARBRetrospective cohort studyAssociation of ageLogistic regression analysisCardiovascular eventsReceptor blockersAdjusted analysisBetter prognosisEnzyme inhibitorsMedicationsCommunity settingsStatinsPreventionIndividual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasisAdherence to Guideline‐Recommended Therapy—Including Supervised Exercise Therapy Referral—Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry
Saxon JT, Safley DM, Mena‐Hurtado C, Heyligers J, Fitridge R, Shishehbor M, Spertus JA, Gosch K, Patel MR, Smolderen KG. Adherence to Guideline‐Recommended Therapy—Including Supervised Exercise Therapy Referral—Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. Journal Of The American Heart Association 2020, 9: e012541. PMID: 31973609, PMCID: PMC7033887, DOI: 10.1161/jaha.119.012541.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmbulatory Care FacilitiesAustraliaCardiovascular AgentsExercise TherapyFemaleGuideline AdherenceHealthcare DisparitiesHumansMaleMiddle AgedNetherlandsPeripheral Arterial DiseasePractice Guidelines as TopicPractice Patterns, Physicians'Prospective StudiesQuality Indicators, Health CareReferral and ConsultationRegistriesUnited StatesConceptsSupervised exercise therapyPeripheral artery diseaseGuideline-recommended therapiesMedian odds ratioPORTRAIT registryAntiplatelet medicationsPAD symptomsOdds ratioSpecialty clinicSpecialty care facilityEvidence-based careCessation counselingExercise therapyCurrent smokersArtery diseaseCare facilitiesPatientsTherapy/counselingUS sitesReferralTherapyStatinsProcedural databaseQuality measuresMedications
2019
Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction
Sposito A, Carvalho L, Moura F, Campos-Staffico A, Cintra R, Nadruz W, Almeida O, Quinaglia e Silva J. Statin Short-term Inhibition of Insulin Sensitivity and Secretion During Acute Phase of ST-Elevation Myocardial Infarction. Scientific Reports 2019, 9: 16401. PMID: 31704948, PMCID: PMC6841947, DOI: 10.1038/s41598-019-52111-x.Peer-Reviewed Original ResearchConceptsEuglycemic hyperinsulinemic clampMyocardial infarctionInsulin sensitivityAcute phaseShort-course treatmentInfluence glucose homeostasisAssociated with mortalityDose-dependent mannerStable patientsClinical outcomesProspective studyStatinsHyperinsulinemic clampPatientsExperimental modelGlucose homeostasisHOMA2DaysCharacteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults.
Lu J, Lu Y, Yang H, Bilige W, Li Y, Schulz W, Masoudi FA, Krumholz HM. Characteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults. Annals Of Internal Medicine 2019, 170: 298-308. PMID: 30776800, DOI: 10.7326/m18-1932.Peer-Reviewed Original ResearchConceptsHigh CVD riskCVD riskHigh riskHigh cardiovascular disease riskCardiovascular risk increasesHigh cardiovascular riskOverall study populationCardiovascular disease riskBody mass indexMultivariable mixed modelsNational Health CommissionAntihypertensive medicationsAspirin useCardiovascular riskCVD screeningMass indexStudy populationChinese adultsHan ethnicityDisease riskStatinsMixed modelsHealth CommissionSocioeconomic statusPopulation subgroups
2018
Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer
Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer. Pigment Cell & Melanoma Research 2018, 32: 292-302. PMID: 30281931, PMCID: PMC6590911, DOI: 10.1111/pcmr.12742.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Line, TumorCell ProliferationColorectal NeoplasmsDrug Resistance, NeoplasmDrug SynergismHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLung NeoplasmsMaleMelanomaMevalonic AcidMice, NudeMitogen-Activated Protein KinasesPrenylationProtein Kinase InhibitorsProtein Processing, Post-TranslationalSignal TransductionConceptsUseful adjunctive therapyHMG-CoA reductase inhibitorsAnti-tumor effectsAdjunctive therapyInhibition of isoprenylationLung cancerMEK inhibitionReductase inhibitorsMAPK blockadeDriver mutationsAdditional studiesStatinsTherapyMelanomaTumorsVemurafenibMAPK pathwayDownstream metabolitesInhibitionMAPKAdjunctiveColorectalSelumetinibBlockadeCancerStatin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
Nanna MG, Navar AM, Wang TY, Mi X, Virani SS, Louie MJ, Lee LV, Goldberg AC, Roger VL, Robinson J, Peterson ED. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. Journal Of The American Heart Association 2018, 7: e008546. PMID: 29739801, PMCID: PMC6015311, DOI: 10.1161/jaha.118.008546.Peer-Reviewed Original ResearchConceptsLipid Management (PALM) registryHigh-dose statinsHigh-intensity statinsStatin useOlder patientsSecondary preventionManagement RegistryPrimary preventionProvider assessmentCardiology/American Heart Association guidelinesAmerican Heart Association guidelinesMultivariable logistic regression modelRoutine community practiceHeart Association guidelinesCurrent statin usersCurrent statin useYears of ageLogistic regression modelsStatin usersYounger patientsPatient surveyAssociation guidelinesAmerican CollegeStatinsPatientsIndividual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer.
Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.6_suppl.202.Peer-Reviewed Original ResearchHigh-risk CaPCAP mortalityM1 diseaseHazard ratioTime-varying Cox proportional hazards modelsHigh-risk prostate cancerCox proportional hazards modelHigh-risk CaP.Post-diagnostic useProstate cancer mortalityUse of statinsPopulation-based studyEffect of statinsProstate cancer metastasisCause of deathProportional hazards modelMetformin useSEER databaseRandomized trialsCancer mortalityProstate cancerMedicare filesStatinsHazards modelMetforminDoes spotty calcification attenuate the response of nonculprit plaque to statin therapy?: A serial optical coherence tomography study
Afolabi A, Mustafina I, Zhao L, Li L, Sun R, Hu S, Zhang S, Jia H, Guilio G, Yu B. Does spotty calcification attenuate the response of nonculprit plaque to statin therapy?: A serial optical coherence tomography study. Catheterization And Cardiovascular Interventions 2018, 91: 582-590. PMID: 29359491, DOI: 10.1002/ccd.27496.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary AngiographyCoronary Artery DiseaseCoronary VesselsFemaleFibrosisHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlaque, AtheroscleroticPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTomography, Optical CoherenceTreatment OutcomeVascular CalcificationConceptsStatin therapyOptical coherence tomographyFibrous cap thicknessSpotty calcificationIntensity statinsModerate statin therapyPresence of spotty calcificationBaseline to 6Lipid-rich plaquesModerate statinsLipid arcCalcification groupCoherence tomographyStatinsTherapyPlaque characteristicsPlaque stabilityCalcificationPlaque progressionMonthsPlaquePatientsVulnerable plaquesMarkers of vulnerable plaqueBaseline
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply